|
|
|
 |
 |
|
       |
|
|
|
Licensing | Erythropoietin  Erythropoietin (EPO) is a glycoprotein that stimulates red blood cell production and is normally produced in the kidney and liver. Nearly all renal failure patients undergoing dialysis suffer from chronic anemia. In 1989, Amgen introduced a genetically engineered erythropoietin -EPOGEN® (Epoietin alpha)- for the treatment of anemia in chronic renal failure patients. Although the market for EPO is increasing, future sales are adversely affected by the high cost of the product and limited life remaining on patents for the first generation of EPO. Protein Sciences has cloned and expressed human EPO using BEVS technology. Exceptionally high levels of rEPO are secreted into protein-free medium using PSC's proprietary serum free expresSF+® cell line. Baculovirus derived rEPO is more active than natural EPO with a biological activity of >200,000 Units/mg in a standard EPO biological assay using murine myeloid cells expressing the EPO receptor. Protein Sciences seeks a partner for the clinical development of rEPO and partners experienced in the formulation and delivery of recombinant proteins. For more information, please contact Manon Cox, Vice President, Chief Operating Officer. |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
